Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size: 2022 VS 2030
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Therapeutics
4.1.3 Diagnostics
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2024-2030
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, 2018-2030
7 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies Profiles
7.1 Siemens Healthcare
7.1.1 Siemens Healthcare Company Summary
7.1.2 Siemens Healthcare Business Overview
7.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.1.4 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Siemens Healthcare Key News & Latest Developments
7.2 Celerion
7.2.1 Celerion Company Summary
7.2.2 Celerion Business Overview
7.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.2.4 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Celerion Key News & Latest Developments
7.3 ZyVersa Therapeutics, Inc.
7.3.1 ZyVersa Therapeutics, Inc. Company Summary
7.3.2 ZyVersa Therapeutics, Inc. Business Overview
7.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.3.5 ZyVersa Therapeutics, Inc. Key News & Latest Developments
7.4 Cisbio
7.4.1 Cisbio Company Summary
7.4.2 Cisbio Business Overview
7.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.4.4 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Cisbio Key News & Latest Developments
7.5 Regeneron Pharmaceuticals, Inc.
7.5.1 Regeneron Pharmaceuticals, Inc. Company Summary
7.5.2 Regeneron Pharmaceuticals, Inc. Business Overview
7.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.5.4 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Regeneron Pharmaceuticals, Inc. Key News & Latest Developments
7.6 BioPredictive
7.6.1 BioPredictive Company Summary
7.6.2 BioPredictive Business Overview
7.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.6.4 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.6.5 BioPredictive Key News & Latest Developments
7.7 Echosens
7.7.1 Echosens Company Summary
7.7.2 Echosens Business Overview
7.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.7.4 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Echosens Key News & Latest Developments
7.8 Genfit
7.8.1 Genfit Company Summary
7.8.2 Genfit Business Overview
7.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.8.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Genfit Key News & Latest Developments
7.9 Enterome
7.9.1 Enterome Company Summary
7.9.2 Enterome Business Overview
7.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.9.4 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Enterome Key News & Latest Developments
7.10 NGM Biopharmaceuticals
7.10.1 NGM Biopharmaceuticals Company Summary
7.10.2 NGM Biopharmaceuticals Business Overview
7.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Major Product Offerings
7.10.4 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global Market (2018-2023)
7.10.5 NGM Biopharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2024-2030
Table 30. Siemens Healthcare Company Summary
Table 31. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 32. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Siemens Healthcare Key News & Latest Developments
Table 34. Celerion Company Summary
Table 35. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 36. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Celerion Key News & Latest Developments
Table 38. ZyVersa Therapeutics, Inc. Company Summary
Table 39. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 40. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. ZyVersa Therapeutics, Inc. Key News & Latest Developments
Table 42. Cisbio Company Summary
Table 43. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 44. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Cisbio Key News & Latest Developments
Table 46. Regeneron Pharmaceuticals, Inc. Company Summary
Table 47. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 48. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Regeneron Pharmaceuticals, Inc. Key News & Latest Developments
Table 50. BioPredictive Company Summary
Table 51. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 52. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. BioPredictive Key News & Latest Developments
Table 54. Echosens Company Summary
Table 55. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 56. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Echosens Key News & Latest Developments
Table 58. Genfit Company Summary
Table 59. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 60. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Genfit Key News & Latest Developments
Table 62. Enterome Company Summary
Table 63. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 64. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Enterome Key News & Latest Developments
Table 66. NGM Biopharmaceuticals Company Summary
Table 67. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offerings
Table 68. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. NGM Biopharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Type in 2022
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Application in 2022
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2022
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 16. US Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 20. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 28. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 34. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share, 2018-2030
Figure 37. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 41. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Industry Market Size
